ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

Company Overview

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products. Through its acquisition of Alimera Sciences, ANI expanded its ophthalmology business with products such as ILUVIEN and YUTIQ, which are used in the treatment of retinal diseases. The company also operates pharmaceutical manufacturing and development capabilities in the United States.

ANI primarily serves the U.S. prescription pharmaceutical market through commercial, specialty and institutional channels. The company’s history includes the expansion of its product portfolio through acquisitions and the development of higher-value specialty medicines alongside its established generic and branded products. Nikhil Lalwani serves as ANI Pharmaceuticals’ president and chief executive officer.

Key Stats

• Today's Range: $69.90 to $72.31
• 50-Day Range: $70.16 to $82.63
• 52-Week Range: $69.58 to $97.00
• Volume: 269,202 shs
• Average Volume: 437,832 shs
• Market Capitalization: $1.61 billion
• P/E Ratio: 15.12
• Dividend Yield: N/A
• Price Target: $99.60
• Consensus Rating: Hold

ANI Pharmaceuticals Stock Analysis - MarketRank™

ANI Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 110th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

ANI Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

ANI Pharmaceuticals has a consensus price target of $99.60, representing about 42.0% upside from its current price of $70.16.

Amount of Analyst Coverage

ANI Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.38%

Earnings Growth

Earnings for ANI Pharmaceuticals are expected to grow by 8.38% in the coming year, from $7.76 to $8.41 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ANI Pharmaceuticals is 15.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of ANI Pharmaceuticals is 15.12, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.31.

Price to Earnings Growth Ratio

ANI Pharmaceuticals has a PEG Ratio of 2.28. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ANI Pharmaceuticals has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.54% of the float of ANI Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ANI Pharmaceuticals has a short interest ratio ("days to cover") of 7.16.

Change versus previous month

Short interest in ANI Pharmaceuticals has recently increased by 40.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ANI Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ANI Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.90

News Sentiment

ANI Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,856,960.00 in company stock.

Percentage Held by Insiders

8.10% of the stock of ANI Pharmaceuticals is held by insiders.

Percentage Held by Institutions

76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ANIP
• Previous Symbol: NASDAQ:BPAX
• CIK: 1023024
• Web: www.anipharmaceuticals.com
• Phone: (218) 634-3500
• Fax: 218-634-3540
• Employees: 970
• Year Founded: 1996

Price Target and Rating

• Average Price Target for ANI Pharmaceuticals: $99.60
• High Price Target: $119.00
• Low Price Target: $85.00
• Potential Upside/Downside: +42.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.64
• Trailing P/E Ratio: 15.12
• Forward P/E Ratio: 9.04
• P/E Growth: 2.28
• Net Income: $78.34 million
• Net Margins: 11.07%
• Pretax Margin: 14.57%
• Return on Equity: 27.37%
• Return on Assets: 10.47%

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 2.91
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: $883.37 million
• Price / Sales: 1.82
• Cash Flow: $9.84 per share
• Price / Cash Flow: 7.13
• Book Value: $24.03 per share
• Price / Book: 2.92

Miscellaneous

• Outstanding Shares: 22,970,000
• Free Float: 21,109,000
• Market Cap: $1.61 billion
• Optionable: Optionable
• Beta: 0.50